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Introduction: Until now, there are several reports on cutaneous manifestations in
COVID-19 patients. However, the link between skin manifestations and the severity of the
disease remains debatable. We conducted a systematic review to evaluate the temporal
relationship between different types of skin lesions and the severity of COVID-19.
Methods: A systematic search was conducted for relevant studies published between
January and July 2020 using Pubmed/Medline, Embase, and Web of knowledge. The
following keywords were used: “SARS-CoV-2” or “COVID-19” or “new coronavirus”
or “Wuhan Coronavirus” or “coronavirus disease 2019” and “skin disease” or “skin
manifestation” or “cutaneous manifestation.”
Results: Out of 381 articles, 47 meet the inclusion criteria and a total of 1,847
patients with confirmed COVID-19 were examined. The overall frequency of cutaneous
manifestations in COVID-19 patients was 5.95%. The maculopapular rash was the
main reported skin involvement (37.3%) commonly occurred in middle-aged females
with intermediate severity of the disease. Forty-eight percentage of the patients had a
mild, 32% a moderate, and 20% a severe COVID-19 disease. The mild disease was
mainly correlated with chilblain-like and urticaria-like lesions and patients with vascular
lesions experienced a more severe disease. Seventy-two percentage of patients with
chilblain-like lesions improved without any medication. The overall mortality rate was
4.5%. Patients with vascular lesions had the highest mortality rate (18.2%) and patients
with urticaria-like lesions had the lowest mortality rate (2.2%).
Conclusion: The mere occurrence of skin manifestations in COVID-19 patients is not
an indicator for the disease severity, and it highly depends on the type of skin lesions.
Chilblain-like and vascular lesions are the ends of a spectrum in which from chilblain-like
to vascular lesions, the severity of the disease increases, and the patient’s prognosis
worsens. Those with vascular lesions should also be considered as high-priority patients
for further medical care.
Keywords: COVID-19, coronavirus – COVID-19, skin manifestations, skin - pathology, systematic literature search,
disease severity, mortality, prognosis
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INTRODUCTION
A viral outbreak caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) emerged from Wuhan, China in
late December 2019 (1). The disease was named coronavirus
disease 2019 (COVID-19) by World Health Organization
(WHO) and was declared as a pandemic on 11 March 2020
(2). After 1 year from the beginning of the pandemic, the
full spectrum of COVID-19 presentations and its relationship
with disease severity is still unknown. Fever, cough, chills,
dyspnea, myalgia, and sore throat are the most common clinical
presentations of COVID-19 and as time goes on, different other
manifestations have been reported (3). Recently, skin lesions
have been described as potential manifestations of COVID-
19 (4–6). The cutaneous changes reported to date include
maculopapular rash, vesicular lesions, urticaria-like lesions, and
chilblain-like lesions (4–8). Some of these skin manifestations
arise before the signs and symptoms more commonly associated
with COVID-19, suggesting that they could be presenting signs
of COVID-19 (9). However, the link between skin manifestations
and the severity of the disease remains debatable. Due to the
great variety of reported dermatologic presentations as well
as the inconsistency of data on the association between skin
presentations of COVID-19 with poor outcome, we aimed to
conduct a comprehensive systematic review on the clinical
and histopathological characteristics of skin manifestations in
relation to other features of confirmed COVID-19 patients and
to evaluate the temporal relationship between different types of
skin lesions and the severity of COVID-19.
METHODS
This review conforms to the “Preferred Reporting Items
for Systematic Reviews and Meta-Analyses” (PRISMA)
statement (10). Registration: PROSPERO (pending registration
ID: 215422).
Search Strategy and Selection Criteria
To investigate the prevalence and characteristics of cutaneous
manifestations in COVID-19 patients, a systematic search was
conducted for relevant studies published between January and
July 2020 using Pubmed, Embase, and Web of knowledge.
The following search terms were used (designed using MeSH
keywords and Emtree terms): “SARS-CoV-2” or “COVID-19”
or “new coronavirus” or “Wuhan Coronavirus” or “coronavirus
disease 2019” and “skin disease” or “skin manifestation”
or “cutaneous manifestation.” Only studies included if they
contained data about the skin manifestation in patients with
confirmed COVID-19. There were no language restrictions. We
got help from the Google Translate system for non-English
papers. Review articles, duplicate publications, and articles with
no relevant data were excluded from the analysis. Two authors
independently screened the remaining articles. Finally, selected
data were extracted from the full-texts of eligible publication by
other investigators of the team.
Data Extraction
Data about the first author’s name, date of publication,
country, number of COVID-19 patients, number of cases with
skin manifestations, age, gender, location and type of skin
manifestations, associated cutaneous symptoms, the onset of
skin lesions with systemic symptoms, the median duration of
the lesions, treatment strategies and main histological findings
of the lesions as well as comorbidities, associated symptoms,
drug history, laboratory findings, severity and outcome of
the patients were selected for further analysis. All cutaneous
presentations related to COVID-19 were categorized into six
groups: chilblain-like, vesicular, urticaria-like, maculopapular,
vascular, and miscellaneous (lesions that we couldn’t subscribe
to any of the groups). Petechiae, purpura, livedo, and necrosis
were classified into vascular lesions. Two authors (PJ, BH)
independently extracted the data from the selected studies. The
data was jointly reconciled, and disagreements were discussed
and resolved between review authors (PJ, BH, MJN).
Quality Assessment
The critical appraisal checklist for case reports provided by the
Joanna Briggs Institute (JBI) was used to perform a quality
assessment of the studies (11).
RESULTS
At the first round of review, 381 articles were selected. After
removing the duplicates and studies that did not meet the
entry criteria, 88 full texts were finally selected for further
assessment. Of these, only 47 articles had the characteristics
appropriated for systematic review and were entered into the
data extraction (Figure 1). Most of the studies were case reports
(47%, N: 22) followed by case series (42.4%, N: 20), retrospective
hospital/private section-based study (6.4%, N: 3), and cross-
sectional (4.2%, N: 2). Thirteen articles were originated from
Italy, 11 from Spain, 10 from France, 5 from the USA, and others
from Belgium, China, Thailand, Kuwait, Indonesia, Russia,
Turkey, and Singapore. Information of the 47 analyzed articles
can be found in Table 1.
A total of 1,847 patients with confirmed COVID-19 (based on
positive RT-PCR or positive antibody tests) were examined in 47
articles, of which 597 patients had different skin manifestations.
The overall frequency of cutaneous manifestations in COVID-19
patients was 5.95%.
Characteristics of the Cutaneous Lesions
in Confirmed COVID-19 Patients
The maculopapular rash was the main reported skin involvement
(37.3%) followed by chilblain-like lesions (18.4%). The
prevalence rate of vesicular and urticaria-like lesions was
15% (Table 4).
The mean age of patients with cutaneous manifestations was
53.3 (ranging from 16 to 92) years. Chilblain-like lesions were
more common in younger patients (mean age: 40.7 years) and
vascular lesions were more common in the elderly (mean age:
72.3 years).
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FIGURE 1 | Flow chart of study selection for inclusion in the systematic review and meta-analysis.
The prevalence of skin lesions was slightly higher in
females than males (54 vs. 46%). Urticaria-like, chilblain- like
and miscellaneous lesions were more frequent among females
(Table 4). Vascular lesions were more frequent in males (61%).
The prevalence of vesicular and maculopapular lesions was
almost the same in men and women (51 and 49%).
Trunk, lower limb, and upper limb were the main involved
regions. Chilblain-like and vascular lesions were more common
in acral areas and except for maculopapular lesions, others were
commonly located in the trunk. The maculopapular lesions were
more common in extremities. The involvement of palms and
soles were rare. Mucous membrane involvement was reported in
all types of skin lesions particularly maculopapular and vascular
lesions, but it was not reported in chilblain-like lesions (Table 4).
Vesicular rashes could have diffused polymorphic or localized
monomorphic patterns (27, 37).
Out of 597, 397 (66%) of the patients had associated
cutaneous symptoms. Pruritus was the most prominent (238,
60%) particularly in vesicular lesions (89%). Pain was the most
frequent symptom in chilblain-like lesions (63.5%) (see Table 4).
In the majority of patients (89.5%), dermatologic
manifestations presented after (55%) or at the same time
(34.5%) with the onset of systemic symptoms of COVID-
19. Urticaria-like lesions appeared usually as a concomitant
symptom (47%). In 3.5% of patients particularly with chilblain-
like lesions, skin manifestations were the only presentation of
COVID-19. In 7% of patients, skin manifestations occurred
before the systemic symptoms, particularly in chilblain-like
lesions (Table 4).
The median duration of skin lesions was about 9 days ranging
from 1 to 18 days (Table 4). Urticaria-like lesions had the least
duration (5 days) and chilblain-like lesions had themost duration
(14 days).
No skin biopsy or histological examination of urticaria-
like lesions was performed. Therefore, the following results are
related to other types of skin lesions.
Perivascular lymphocytic infiltration, spongiotic and interface
dermatitis, and vacuolization or keratinocyte necrosis were the
common histologic findings in skin biopsies, except for vesicular
lesions. In vesicular lesions, the absence of inflammatory
infiltrates, atrophic epidermis, and hyperkeratosis was reported.
In almost all types of lesions (except maculopapular and
vesicular lesions) thrombotic vasculopathy and red blood
cell extravasation were present. Langerhans cell aggregations
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TABLE 1 | Characteristics of the included studies.





No. of the patient(s)
with skin
manifestations
Hunt, M. (12) USA Mar 28-2020 Case report 20 1M 1 1
*Recalcati, S. (6) Italy Apr 7-2020 Retrospective
hospital-based study
– – 88 18
*Joob, B. (13) Thailand Apr 7-2020 Retrospective
hospital-based study
40.5 4M, 37 F 41 1
Zhang, Y. (14) China Apr 7-2020 Case series 59 4M, 3 F 7 7
Fiehn, C. (15) Spain Apr 15-2020 Case report 28 1 F 1 1
Mahé, A. (16) France Apr 16-2020 Case report 46 1 F 1 1
Zulfiqar, A. A. (17) France Apr 16-2020 Case report 65 1 F 1 1
*Magro, C. (18) USA Apr 18-2020 Case series 54.6 3M, 2 F 5 3
Morey-Olive, M. (19) Spain Apr 22-2020 Case series Boy: 6 years
Girl: 2 months
1M, 1 F 2 2
Najarian, D. J. (20) USA Apr 22-2020 Case report 58 1M 1 1
Gianotti, R. (21) Italy Apr 29-2020 Case series 68 1M, 2 F 3 3
Gianotti, R. (22) Italy Apr 30-2020 Case series – – 5** 5**
Sanchez, A. (23) France Apr 30-2020 Case report Elderly – 1 1
Galván Casas, C. (24) Spain Apr 30-2020 Cross-sectional 56.3 113M, 121 F 234 234
Ahouach, B. (25) France May 1-2020 Case report 57 1 F 1 1
Quintana-Castanedo, L.
(26)
Spain May 1-2020 Case report 61 1M 1 1
Marzano, A. V. (27) Italy May 1-2020 Case series 56.4 16M, 6 F 22 22
Zengarini, C. (28) Italy May 3-2020 Case report 67 1 F 1 1
Alramthan, A. (29) Kuwait May 5-2020 Case series 31 2 F 2 2
Henry, D. (30) France May 5-2020 Case report 27 1 F 1 1
*Recalcati, S. (31) Italy May 6-2020 Case series 72.2 58M, 49 F 107 3
*Tammaro, A. (32) Italy May 6-2020 Case series – – 130 + X*** 2 + 1***
van Damme, C. (33) Belgium May 6-2020 Case report 71 1M 1 1
Avellana Moreno, R. (34) Spain May 6-2020 Case report 32 1 F 1 1
Amatore, F. (35) France May 6-2020 Case report 39 1M 1 1
Suarez-Valle, A. (36) Spain May 8-2020 Case series – – 3 3
Fernandez-Nieto, D. (37) Spain May 8-2020 Case series 45 6M, 18 F 24 24
Paolino, G. (38) Italy May 8-2020 Case report 37 1 F 1 1
Diaz-Guimaraens, B. (7) Spain May 8-2020 Case report 48 1M 1 1
Bouaziz, J. D. (39) France May 8-2020 Case series – – 14 14
Locatelli, A. G. (40) Italy May 9-2020 Case report 16 1M 1 1
Jimenez-Cauhe, J. (41) Spain May 9-2020 Case series 66.7 4 F 4 4
Robustelli Test, E. (42) Italy May 10-2020 Case report 70 1 F 1 1
Gunawan, C. (43) Indonesia May 10-2020 Case report 51 1M 1 1
*de Masson, A. (44) France May 28-2020 Retrospective private
practices-based study
– – 25 7
Freeman, E. E. (45) USA May 30-2020 Case series 41 12M, 11 F 23 23
Bosch-Amate, X. (46) Spain June 03-2020 Case report 79 1 F 1 1
Reymundo, A. (47) Spain June 04-2020 Case series 66.6 2M, 5 F 7 7
Gargiulo, L. (48) Italy June 07-2020 Case report 72 1 F 1 1
Freeman, E. E. (45) USA June 23-2020 Case series 44 78M, 93 F 165**** 165****
*Askin, O. (49) Turkey June 24-2020 Cross-sectional NM NM 122 34
Ciccarese, G. (50) Italy June 24-2020 Case report 19 1 F 1 1
*Matar, S. (51) France June 26-2020 Case series 55.6 6M, 2 F 759 8
Ho, W. Y. B. (52) Singapore June 26-2020 Case series 59 1M, 1 F 2 2
Potekaev, N. N. (53) Russia July 03-2020 Case series 62.2 7M, 5 F 12 12
(Continued)
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TABLE 1 | Continued





No. of the patient(s)
with skin
manifestations
Le Cleach, L. (54) France July 06-2020 Case series 34 3M, 7 F 10 10
Proietti, I. (55) Italy July 22-2020 Case report 6 months 1M 1 1
*Articles that are included for calculating the prevalence of cutaneous manifestations in confirmed COVID-19 patients.
**Total population of cases was 8 but data of 5 patients were available only.
***Tammaro et al. visited 130 patients in a hospital in Rome in which 2 patients had cutaneous manifestations. Also, they visited undetermined (X) patients in Barcelona in which there was
a patient with cutaneous manifestation. Note that for calculating the prevalence number we excluded the latter patient (because of the undetermined number of total case population).
****Total population of confirmed COVID-19 patients was 171 but data of 165 patients were available only.
were seen within the epidermis in maculopapular lesions.
Telangiectatic blood vessels were seen within the dermis of
vascular and miscellaneous lesions. Virally-induced cytopathic
alterations were absent according to reports on the miscellaneous
category. Striking vascular and dermal deposits of complement
factors (C5b-9, C3d, C4d) and IgM were present in four vascular
rashes. Some studies performed an RT-PCR test on skin samples
of maculopapular and vesicular lesions and the results were all
negative for SARS-CoV-2. More details can be found in Table 2.
Most lesions required systemic corticosteroids (47%) or had
spontaneous remission (23.5%). Antihistamines were the most
widely usedmedication especially for urticaria-like lesions (57%).
Systemic corticosteroids were commonly used in vascular lesions
(71%) (Tables 2, 4).
Characteristics of the Confirmed COVID-19
Patients With Skin Manifestations
The overall prevalence of comorbidities among patients with
skin manifestations was 17.9% (Table 4). Hypertension (39%),
diabetes (23%), and dermatologic diseases (20%) were the
most frequent comorbidities, respectively. Utmost cases with
comorbidity were across the patients with maculopapular lesions
(40%). Previous dermatologic illnesses were most common in
patients with vesicular lesions (Table 4). Cardiovascular disease,
hypertension, and obstructive lung diseases were common
comorbidities amongst patients with vascular lesions (Table 4).
Rheumatologic diseases were more frequent in patients with
chilblain-like lesions (30%). Diabetes was seen commonly in
patients with urticaria-like lesions (46%).
Fever (72%), cough (61%), fatigue/myalgia (51%),
and dyspnea (46%) were the most common associated
symptoms amongst the patients. Fever was more frequent
in patients with vascular lesions (84%) and less frequent in
patients with chilblain-like lesions (39.5%). Headache (41%),
dysosmia/hyposmia (27.5%), nasal congestion/coryza (19%), and
irritability/confusion (10%) were mainly seen in patients with
vesicular lesions. Seventeen percentage of patients with chilblain-
like lesions, 5% of patients with urticaria-like lesions, and 1%
of patients with maculopapular lesions were asymptomatic.
Bleeding presentations like epistaxis were seen just in patients
with vascular lesions (Tables 3, 4).
Elevated D-dimer was the main laboratory finding in most
of the cases, especially in patients with chilblain-like (100%)
and vascular (46%) lesions. Disruption of coagulation condition
(increase in PT, INR, and fibrinogen) was reported in patients
with chilblain-like and vascular lesions (Tables 3, 4).
Regarding the drug history and medication regimen used
for COVID-19, data of 389 out of 597 cases were available,
most of which related to maculopapular and urticaria-like
lesions. Fifty-two percentage of all cases and 72% of cases
with chilblain-like lesions underwent symptomatic treatment
with paracetamol, etc., or recovered without any medication.
Chloroquine/hydroxychloroquine was the most common
medication used in patients (45%). Details in Tables 3, 4.
Most patients hadmild disease (48%). Themajority of patients
with chilblain-like lesions had mild disease (82%) and the
majority of patients with vascular lesions had severe disease
(68%). Also, most of the patients with maculopapular lesions
were moderate (43%) regarding severity (Tables 3, 4).
The overall mortality rate among COVID-19 patients with
cutaneousmanifestations was 4.5%. Patients with vascular lesions
had the highestmortality rate (18.2%) and patients with urticaria-
like lesions had the lowest mortality rate (2.2%).
Details indicating characteristics of the lesions and the
patients are shown in Tables 2–4.
DISCUSSION
After 1 year from the beginning of COVID-19 pandemic, the
world is still facing a crisis. According to the current literature,
more than half of the patients are asymptomatic leading to
uncontrolled transmission of the virus (57–60). Recognizing
COVID-19 related cutaneousmanifestationsmay assist clinicians
in early diagnosis of disease, before the development of
respiratory symptoms, and may also be used to identify
complications requiring treatment. The current study found that
10.5% of the COVID-19 patients reported skin lesions before the
initiation of other symptoms or as their chief complaint. On the
other hand, considering cutaneous manifestations is important
to make the right diagnosis; as Joob et al. reported a COVID-
19 patient with petechiae misdiagnosed with dengue fever (13).
Our data demonstrated that 34.5% of cutaneous manifestations
occurred at the same time with other symptoms particularly
urticaria-like lesions (47%). It may suggest that urticaria-like
lesions may be a diagnostic sign for COVID-19. The rest of the
skin manifestations appeared later in the course of the disease































TABLE 2 | Characteristics of the cutaneous lesions in confirmed COVID-19 patients.






Main histologic findings Rash
treatment
Locatelli, A. G. (40) Chilblain-like Dorsal aspects of the fingers Erythematous-
oedematous macules and
plaques (Chilblain-like)
Asymptomatic After – Oedema of the papillary
dermis, superficial and deep
lymphocytic infiltrate in a
peri-vascular and strong
peri-eccrine pattern; no signs
of endothelial damage.
consistent with a diagnosis of
chilblains
–
Alramthan, A. (29) Chilblain-like Dorsal aspect of fingers
bilaterally, subungual area of
the thumb
Red-purple papules,
diffused erythema in the
subungual area
– Chief complaint – – –





between 0.5 and 1 cm,
sharply defined, with no
retiform borders
– 23 days after 14 days Ischemic necrosis affecting














Before (4), After (11),
At the same time (3),
No other COVID-19
symptoms (5)




consistent with pernio vs.
connective tissue disease. No
thrombi were noted.
–
Le Cleach, L. (54) Chilblain-like Acral area of hand and foot,
dorsum of toes and soles,
lateral part of the foot
Typical chilblains, severe





– After/Before – Vacuolization or apoptosis of
keratinocytes, superficial and









Najarian, D. J. (20) Maculopapular Legs, thighs, forearms, arms,
shoulders, back, chest, and
abdomen (sparing the face,
hands, feet, and mucosa)
Morbilliform erythematous
macules and patches
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Main histologic findings Rash
treatment













RT-PCR on a fresh skin
biopsy specimen
No
Hunt, M. (12) Maculopapular Trunk and extremities (sparing




with a viral exanthem)
Non-pruritic At the same time – – –
Ahouach, B. (25) Maculopapular Trunk, limbs Diffuse fixed erythematous
blanching maculopapular
lesions
Burning – – Spongiosis, basal cell
vacuolation and mild
perivascular lymphocytic






Maculopapular Face, neck, thorax, abdomen,
buttocks, extremities including
folds and scalp, respecting








scaly reaction occurred on
the fourth day after the
rash started
Pruritus 6 day after 4 days – –
Reymundo, A. (47) Maculopapular Trunk (7), proximal upper
limbs (6), proximal lower limbs
(1)







Morey-Olive, M. (19) Maculopapular (1),
Urticaria-like (1)
Maculopapular: trunk, neck
spreading to the cheeks,
upper and lower extremities
(involving the palms)
Urticaria-like: face, upper
extremities spreading to the
trunk and lower extremities







Pruritus (1) After (1), At the
same time (1)

















































































TABLE 2 | Continued






Main histologic findings Rash
treatment























small blood vessels in the
dermis, spongiotic dermatitis
with exocytosis along with a
large nest of Langerhans cells




microthrombi in the small
dermal vessels.
–
Mahé, A. (16) Miscellaneous Both antecubital fossae
extended to the trunk and
axillary folds
Erythematous rash – 4 days after 5 days – –
Robustelli Test, E.
(42)
Miscellaneous Face, trunk, upper and lower










with small pustules in a
symmetric pattern










Zengarini, C. (28) Miscellaneous Neck, trunk, back, proximal
portions of limbs (sparing the





Moderate pruritus After 7 days Slight superficial perivascular
lymphocytic infiltrate
extremely dilated vessel in the
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Main histologic findings Rash
treatment
Amatore, F. (35) Miscellaneous Upper limbs, chest, neck,
abdomen, and palms (sparing





















Gargiulo, L. (48) Miscellaneous Trunk, upper and lower limbs Erythema multiforme-like
(erythematous and slightly
edematous patches,
along with some isolated
typical target lesions)
Pruritus 10 days Before – Mixed perivascular and
interstitial infiltrate including
lymphocytes, granulocytes,




Ciccarese, G. (50) Miscellaneous Lower limbs, Inner surface of







Asymptomatic 5 days after 12 days – –
Recalcati, S. (6) Miscellaneous (14),
Urticaria-like (3),
Vesiclular (1)




Low or absent pruritus At the same time (8),
After (10)
Few days – –




Pruritus (1) After (2), Before (1) 5, 8, 10 days Perivascular dermatitis with
slight lymphocytic exocytosis









swollen vessels in the dermis
with dense lymphocyte
infiltration, mixed with rare
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Miscellaneous (4) Upper trunk, coalescing in the
back, and then spread to the
face and limbs within 1 week
(without the involvement of
palms and soles), platal









– 19.5 days after 17.5 days Normal basket-weave stratum
corneum, mild to moderate
spongiosis in the epidermis,
dilated vessels filled with
neutrophils, extravasation of















Chilblain-like: acral areas of
hands and feet. usually
asymmetrical
Vesicular: trunk, limbs
Urticaria-like: mostly trunk, a
few cases were palmar
Maculopapular: extremities,



















Fiehn, C. (15) Urticaria-like Both heels Confluent
erythematous-yellowish
papules and plaques
Pruritus 13 days After – – –




Urticaria-like Thighs, arms, and forearms




Mild pruritus Chief complaint 7 days – Antihistamine
Henry, D. (30) Urticaria-like Face, acral area, palm Disseminated
erythematous plaques
(Urticaria), papules in palm
Pruritus Before – – Antihistamine
van Damme, C. (33) Urticaria-like – Extensive acute urticarial
rash
– At the same time – – Bilastine
Paolino, G. (38) Urticaria-like Trunk, neck, face, lower limbs An urticaria-like lesion with
craniocaudal development
Non-pruritic 3 days after 8 days – –
Proietti, I. (55) Urticaria-like Trunk, limbs Giant urticaria with
multiple lesions
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anterior thighs, and lower





Slightly pruritic 3 days after 5 days Perivascular lymphocytic
infiltrate, red cell
extravasation, and focal
papillary edema, along with
focal parakeratosis and








Magro, C. (18) Vascular Buttocks, palms and soles,





– 4 days after – Thrombogenic vasculopathy,







infiltration, absence of clear
vasculitis, Significant vascular
deposits of C5b-9, C3d, and
C4d (in all cases)
–
Recalcati, S. (6) Vascular Acral area, foot Acrocyanosis (2), foot
thrombosis (1)
– – – – –
Zhang, Y (14) Vascular Finger/toe Acro-ischemia including
cyanosis, bulla, and dry
gangrene





Vascular Both legs Retiform
purpuric-violaceous
patches of 15 cm with
some hemorrhagic blisters
and crusts suggestive of
retiform purpura
Pain – – Multiple thrombi occluding
most small-sized vessels of
the superficial and
mid-dermis, deposition of
IgM, C3, C9, and fibrinogen
within superficial-to-deep
dermal blood vessel walls.
–






reported in 7 patients:
exanthema (4),
chickenpox like vesicles
(2), cold urticaria (1),
Vascular lesions were
reported in 7 patients:
violaceous macules with
“porcelain-like”





(1), chilblain (1), eruptive
cherry angioma (1).
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Main histologic findings Rash
treatment
















Vesicular (24) Head (4), anterior trunk (21),
posterior trunk (14), arms (8),
legs (10), palms-soles (2)
18 disseminated pattern
(small papules, vesicles,
and pustules with varying
sizes of up to 7–8mm
diameter, different stages




up to 3–4mm diameter, at





Before (2), At the
same time (3), After
(19)
10 days Intraepidermal vesicles with
mild acantolisis and ballooned
keratinocytes consistent with
a viral infection, negative
SARS-CoV-2 RT-PCR on fluid
content of the vesicles
–





one of the patients, the






















































































TABLE 2 | Continued






Main histologic findings Rash
treatment





Lower limb (6), upper limb (5),
trunk (4), first MTP joints (1),
ankles and dorsal surfaces of










elements of bright pink
color, papulosquamous
rash (pytriasis rosea-like,
absence of the herald
patch), disseminated
pink-red maculopapular
rash resembling that of





Pain (1), Pruritus (1) Before (1), At the












Hand (38), foot (51), face (32),
head (11), neck (26), chest
(49), abdomen (63), back (62),
arm (66), genitals (7),






















































































































































































































































































































































































































































































































































































































































and mainly after the initiation of systemic symptoms (55%)
in our review. Galván Casas et al. suggested the chilblain-like
and vesicular lesions as epidemiological markers for the disease
(24). However, in our study, vesicular lesions (74%) were the
most important cutaneous manifestations usually appearing after
systemic symptoms of the disease.
Most of the patients with skin manifestations were middle-
aged females, while, patients with chilblain-like lesions were
younger (mean age: 40.7 years) and patients with vascular lesions
were older individuals (mean age: 72.3 years). These findings are
along with other studies about the chilblain-like lesions (6, 19, 24,
40). Maculopapular lesions were the most common dermatologic
presentation of COVID-19 patients that commonly appeared at
extremities. It occurred most often in middle-aged patients and
was associated with moderate COVID-19 severity.
The overall mortality rate between the COVID-19 patients
with skin presentations was 4.5%, with the point that there was
the lowest mortality rate among the patients with urticaria-like
lesions (2.2%) and contradictory, there was the highest mortality
rate among the patients with vascular lesions (18.2%). Previous
studies showed a pooled mortality rate of 3.2–6% in patients
with COVID-19 (61, 62). Thus, the mortality rate of COVID-19
patients with skin manifestations is proportionate to the overall
mortality rate of the disease.
Regardless of the type of skin lesions, 80% of COVID-19
patients with cutaneous manifestations experienced a mild and
moderate, and 20% a severe COVID-19 disease. A previous study
from the Chinese Center for Disease Control and Prevention
reported that 81% of COVID-19 patients had a mild, 14% a
severe, and 5% a critical disease (63). We don’t have any specific
data on patients without skin manifestations but comparing the
COVID-19 severity in patients with skin manifestations and
COVID-19 patients, regardless of their symptoms, demonstrates
no obvious difference. Future cohort studies are required to
compare the disease severity and outcome of COVID-19 patients
with and without skin manifestations.
There is a wide range of cutaneous manifestations related
to COVID-19 that in terms of age, associated symptoms,
comorbidity, medication, severity, and mortality, chilblain-
like lesions, and vascular lesions are the ends of this
spectrum. Chilblain-like, urticaria-like, vesicular, maculopapular,
miscellaneous, and vascular lesions are associated with an
increase in COVID-19 severity and worsening the prognosis,
respectively. Vascular lesions were more prevalent inmales (61%)
compared to females (39%). Considering the more severe disease
and higher mortality rate in patients with vascular lesions, we
can conclude that COVID-19 is more severe in males compared
to females. This finding is compatible with our recent article, in
which we assessed the sex-specific risk of mortality in COVID-19
patients (62).
Up to date, there is conflicting information about the
potential possibility of transmitting the virus through the skin
(37, 40, 64). Further investigations are required to identify the
pathophysiology of SARS-COV-2 and to determine whether
patients with long-lasting skin lesions (e.g., chilblain-like lesions)
are capable of infecting other individuals through skin contact
or not.































TABLE 3 | Characteristics of the confirmed COVID-19 patients with skin manifestations.
First author Comorbidity Associated symptoms Drug history Laboratory findings Severity/outcome
Locatelli, A. G. (40) – Dysgeusia, mild diarrhea – – Non-severe
Alramthan, A. (29) – Asymptomatic – – –
Suarez-Valle A. (36) – – – D-dimer↑, fibrinogen↑ Non-severe
de Masson, A. (44) – – – – –
Freeman EE. (45) HTN (2), obstructive lung
disease (2), reumatologic
disease (2)
Fever (9), cough (9), dyspnea
(6), sore throat (5), headache
(7), malaise (4), asymptomatic
(5)
– – Outpatient care only (18), Hospitalized
(5), Death (2)
Le Cleach L. (54) Raynaud syndrome (2) Fever (2), cough (2), dyspnea




– – Outpatient (10)
Najarian, D. J. (20) – Cough, pain in leg and hands Azithromycin, Benzonatate – Non-severe
Sanchez, A. (23) T2D, HTN, peripheral
artery disease, chronic
renal failure
Fatigue, fever, dyspnea, acute
respiratory distress
Cefpodoxime EBV PCR positive (reactivation of
EBV)
Severe/ Death
Hunt, M. (12) – Fever – Lymphopenia, CRP↑ Severe
Ahouach, B. (25) – Fever, dry cough Paracetamol – –
Avellana Moreno, R. (34) – Fever, myalgia, asthenia,
cough, diarrhea
Paracetamol – –
Reymundo A. (47) – – – – –
Morey-Olive, M. (19) Cholestatic liver disease
(1)
Low-grade fever Oral symptomatic treatment Worsening of the markers for
cholestasis
–
Gianotti, R. (22) – Fever, sore throat, cough Levofloxacin (3), HCQ (3) – Mild (2), Moderate (2), Severe (1)
Mahé, A. (16) T2D Fever, asthenia, cough Paracetamol – Non-severe/Survived
Robustelli Test, E. (42) – – Lopinavir/ritonavir, HCQ (3 weeks
before)
– –
Zengarini, C. (28) Moderate obesity, a
history of alcoholism, and
various chronic
morbidities





Amatore, F. (35) – Fever HCQ Blood count: NL, electrolytes: NL,
CRP: NL, anti-DNA antibodies: NL
Gargiulo L. (48) – Fever Paracetamol, Darunavir/cobicistat,
HCQ
– Severe, Death
Ciccarese G. (50) – Fever, sore throat, fatigue,
hyposmia























































































TABLE 3 | Continued
First author Comorbidity Associated symptoms Drug history Laboratory findings Severity/outcome
Gianotti, R. (21) – Fever (2), cough (2), headache
(1), arthralgias (1)
Lopinavir/Ritonavir (1), Heparin (1),
Levofloxacin (2), Ceftriaxone (1),
Azithromycin (1), HCQ (1)
CRP↑, fibrinogen↑, ALT↑, AST↑ Mild (1), Severe (2)
Jimenez-Cauhe J. (41) – – Lopinavir/Ritonavir, HCQ,
Azithromycin, Corticosteroids,
Ceftriaxone
Laboratory tests at the time of skin
lesions showed worsening of one or
more parameters compared to those
at the time of discharge (CRP↑,
D-dimer↑, lymphocyte count↓)
–




– – Pseudo-chilblain: less severe
Vesicular lesions: intermedium
severity
Urticarial and maculopapular lesions:
more severe COVID-19 disease
Livedoid/necrotic lesions: the most
severe disease
















– 4-day history of progressive
cutaneous rash
– – –
Henry, D. (30) – Odynophagia, diffuse
arthralgia, chills, chest pain,
fever
Paracetamol Moderate lymphopenia, CRP↑ Non-severe








General weakness, fever – Mild lymphopenia, CRP↑, LFT (GOT,
GPT, LDH, GGT)↑
Severe/Death
Paolino, G. (38) – 7th postpartum day, fever, dry
cough, myalgia, arthralgia
Paracetamol – –
Proietti I. (55) – Asymptomatic – Normal –
Zulfiqar, A. A. (17) HTN, autoimmune
hypothyroidism
Fatigue, fever, dry cough,
abdominal discomfort,
epistaxis




Joob, B. (13) – Fever, pneumonia, bleeding
presentation (firstly missed



















































































TABLE 3 | Continued
First author Comorbidity Associated symptoms Drug history Laboratory findings Severity/outcome
Diaz-Guimaraens, B. (7) HTN Fever, pleuritic chest pain,
shortness of breath
Telmizartan, HCQ, LR, Azithromycin Lymphopenia, CRP↑, D-dimer↑ Non-severe




diarrhea, chest pain, myalgia
HCQ, Azithromycin, Remdesivir,
prophylactic Enoxaparin
D-dimer↑, INR↑, CH50↑, C3↑, C4↑,
Thrombocytopenia
Severe
Recalcati S. (6) – – – – –
Zhang, Y (14) HTN, DM, CAD Fever, cough, dyspnea,
diarrhea
LMWH D-dimer↑, fibrinogen↑, FDP↑, PT↑ Severe/Death (5)
Bosch-Amate X. (46) – Fever, asthenia, cough,
shortness of breath
HCQ, Azithromycin, LR, LMWH,
Fondaparinux
Leukopenia, CRP↑, D-dimer↑ Hospitalized, Survival
Bouaziz, J. D. (39) – – – – –
Marzano, A. V. (27) – Fever (21), cough (16),
headache (11), weakness
(11), coryza (10), dyspnea (9),
hyposmia (4), hypogeusia (4),
pharyngodynia (1), diarrhea
(1), myalgia (1)
– – Mild (10), Moderate (2), Severe (10)/
Death (3)
Fernandez-Nieto, D. (37) Atopic dermatitis (5),
chronic urticaria (2)
– 7 patients: Lopinavir/Ritonavir (5),
HCQ (6), Azithromycin (2)
– Mild (14), Moderate (9), Severe (1)
Tammaro A. (32) – – – – –
Potekaev NN. (53) – Fever (2), cough (1), weakness
(1), shortness of breath (1)
HCQ (1) – Severe (2)









areata (4), melanoma (3)
Fever (103), cough (92),
dyspnea (64), sore throat (62),
headache (54), diarrhea,
vomiting or nausea (51),
malaise (45), myalgia (35),
irratibility/confusion (27), chest
pain (27), abdominal pain (23),
anosmia (18), dysgeusia (12),
arthralgia (16), rhinorrhea (14),
asymptomatic (11)
Bevacizumab (12), Remdesivir (9),
Lopinavir/Ritonavir (2), supportive
care only (96), anti-malarials (41),
antibiotics (40), serpin inhibitors (6),
IL-6 inhibitors (4), JAK inhibitors (2)
– Out-patient (95), Hospitalized (17),
Non-invasive ventilation or high flow
oxygen, ventilator and/or ECMO
required (24), Death (8)
Matar S. (51) – – – – –
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N (%) 110 (18.4) 89 (15) 89 (15) 223 (37.3) 55 (9.2) 31 (5.2) 597
Sex, N* 97 83 85 219 46 11 541
Male, n (%) 43 (44) 42 (51) 28 (33) 107 (49) 28 (61) 2 (18) 250 (46)
Female, n (%) 54 (56) 41 (49) 57 (67) 112 (51) 18 (39) 9 (82) 291 (54)
Age, mean 40.7 56.1 46.3 56.4 72.3 48 53.3
Rash location
Trunk, n
0 85 91 143 21 23 363
Upper Limb, n 24 44 29 194 8 9 308
Lower Limb, n 53 42 30 188 18 10 341
Head/Neck, n 0 12 20 42 0 7 81
Palms/Soles, n 1 2 2 1 1 1 8
Acral area (Finger, Toe), n 69 0 1 0 18 0 88
The mucous membrane, n 0 2 1 4 4 2 13
Associated cutaneous symptoms,
n (%)
74 (67) 62 (70) 80 (90) 159 (71) 18 (33) 4 (13) 397 (66)
Pruritus, n (%) 28 (38) 55 (89) 22 (27.5) 126 (79) 4 (22) 3 (75) 238 (60)
Burning, n (%) 40 (54) 11 (18) 7 (9) 23 (14) 2 (11) 0 (0) 83 (21)
Pain, n (%) 47 (63.5) 9 (14.5) 6 (7.5) 19 (27) 3 (17) 0 (0) 84 (21)
The onset of the lesions in relation
toother symptoms, N
91 86 85 222 41 17 542
Before, n (%) 10 (11) 5 (6) 5 (6) 14 (6) 1 (2) 1 (6) 36 (7)
Chief complaint, n (%) 13 (14) 0 (0) 3 (3.5) 3 (1) 0 (0) 0 (0) 19 (3.5)
At the same time, n (%) 21 (23) 17 (20) 40 (47) 92 (41) 16 (39) 1 (6) 187 (34.5)
After, n (%) 45 (49) 64 (74) 37 (43.5) 113 (51) 24 (58.5) 15 (88) 298 (55)
Median duration of skin lesions,
day
14 9 5.25 7.4 9.5 9.3 9
Rash treatment, N** 0 0 7 15 5 7 34
Without treatment, n (%) 0 (0) 0 (0) 0 (0) 7 (47) 1 (20) 0 (0) 8 (23.5)
Antihistamines, n (%) 0 (0) 0 (0) 4 (57) 0 (0) 1 (20) 0 (0) 5 (15)
Topical corticosteroids, n (%) 0 (0) 0 (0) 1 (14) 1 (7) 2 (40) 1 (14) 5 (15)
Systemic corticosteroids, n (%) 0 (0) 0 (0) 2 (28.5) 7 (47) 2 (40) 5 (71) 16 (47)
Hydroxychloroquine, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (14) 1 (3)
Comrbidity, N*** (%) 20 (19) 14 (13) 13 (12) 43 (40) 15 (14) 2 (2) 107 (100)
Hypertension 6 (30) 3 (21) 5 (38) 16 (37) 12 (80) 0 (0) 42 (39)
Diabetes 0 (0) 2 (14) 6 (46) 10(23) 6 (40) 1 (50) 25 (23)
Previous dermatologic illness**** 2 (10) 8 (57) 1 (8) 10 (23) 0 (0) 0 (0) 21(20)
Obstructive lung disease 2 (10) 1 (7) 1 (8) 6 (14) 6 (40) 0 (0) 16 (15)
Non-obstructive lung disease 1 (5) 1 (7) 3 (23) 4 (9) 0 (0) 0 (0) 9 (8)
Rheumatologic disease 6 (30) 1 (7) 0 (0) 1 (2) 1 (7) 0 (0) 9 (8)
Chronic kidney disease 0 (0) 0 (0) 1 (8) 6 (14) 0 (0) 0 (0) 7 (6.5)
Cardiovascular disease 1 (5) 0 (0) 0 (0) 3 (7) 2 (13) 0 (0) 6 (6)
Obesity 0 (0) 0 (0) 1 (8) 0 (0) 1 (7) 1 (50) 3 (3)
Obstructive sleep apnea 0 (0) 0 (0) 1 (8) 0 (0) 1 (7) 0 (0) 2 (2)
Dyslipidemia 0 (0) 0 (0) 2 (15) 0 (0) 0 (0) 0 (0) 2 (2)
Liver disease 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 1 (1)
Peripheral artery disease 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 1 (1)
Autoimmune hypothyroidism 0 (0) 0 (0) 0 (0) 0 (0) 1 (7) 0 (0) 1 (1)
Hyperuricemia 0 (0) 0 (0) 1 (8) 0 (0) 0 (0) 0 (0) 1 (1)
Stroke 0 (0) 0 (0) 1 (8) 0 (0) 0 (0) 0 (0) 1 (1)
Alcoholism 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50) 1 (1)
(Continued)
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Associated symptoms, N***** 96 58 83 210 43 6 496
Fever, n (%) 38 (39.5) 48 (83) 63 (76) 169 (80) 36 (84) 5 (83) 359 (72)
Cough, n (%) 35 (36) 40 (69) 51 (61) 146 (69.5) 31 (72) 1 (17) 304 (61)
Fatigue/Myalgia, n (%) 42 (44) 33 (57) 46 (55) 113 (54) 15 (35) 2 (33) 251 (51)
Dyspnea, n (%) 27 (28) 22 (38) 33 (40) 120 (57) 27 (63) 1 (17) 230 (46)
Headache, n (%) 32 (33) 24 (41) 26 (31) 64 (30) 7 (16) 0 (0) 153 (31)
Nausea/Vomiting/Diarrhea/Abdominal
discomfort, n (%)
17 (18) 14 (24) 31 (37) 77 (37) 14 (32.5) 0 (0) 153 (31)
Dysosmia/Dysgeusia, n (%) 21 (22) 16 (27.5) 22 (26.5) 39 (18.5) 3 (7) 1 (17) 102 (20.5)
Sore throat, n (%) 13 (13.5) 10 (17) 11 (13) 33 (16) 3 (7) 1 (17) 71 (14)
Chest pain, n (%) 2 (2) 4 (7) 8 (10) 12 (6) 2 (5) 0 (0) 28 (6)
Nasal congestion/Coryza, n (%) 5 (5) 11 (19) 5 (6) 4 (2) 0 (0) 0 (0) 25 (5)
Irritability/Confusion 3 (3) 6 (10) 5 (6) 13 (6) 0 (0) 0 (0) 27 (5)
Arthralgia, n (%) 1 (1) 3 (5) 6 (7) 10 (5) 1 (2) 0 (0) 21 (4)
Bleeding presentation, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0) 2 (0.4)
Chills, n (%) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 (0.2)
Odynophagia, n (%) 3 (3) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 4 (0.8)
Asymptomatic, n (%) 16 (17) 0 (0) 4 (5) 3 (1) 0 (0) 0 (0) 23 (5)
Laboratory Findings, N****** 3 0 2 10 26 12 53
D-dimer increase, n (%) 3 (100) 0 (0) 0 (0) 0 (0) 12 (46) 3 (25) 18 (34)
Fibrinogen increase, n (%) 2 (67) 0 (0) 0 (0) 0 (0) 8 (31) 0 (0) 10 (19)
FDP increase, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 7 (27) 0 (0) 7 (13)
PT/INR increase, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 6 (23) 0 (0) 6 (11)
CRP increase, n (%) 0 (0) 0 (0) 1 (50) 3 (30) 3 (11.5) 2 (17) 9 (17)
Leukopenia, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 1 (2)
Leukocytosis, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8) 1 (2)
Lymphopenia, n (%) 0 (0) 0 (0) 1 (50) 2 (20) 1 (4) 2 (17) 6 (11)
Thrombocytopenia, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 2 (8) 1 (8) 3 (6)
LFT increase, n (%) 0 (0) 0 (0) 0 (0) 3 (30) 1 (4) 1 (8) 5 (9)
CH50, C3, C4increase, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 1 (2)
COVID-19 treatment, n (%) 46 40 69 185 39 10 389
Paracetamol, symptomatic or without
treatment, n (%)
33 (72) 21 (52.5) 39 (56.5) 103 (56) 5 (13) 3 (30) 204 (52)
Chloroquine/Hydroxychloroquine, n
(%)
9 (19.5) 16 (40) 27 (39) 90 (49) 26 (67) 8 (80) 176 (45)
Lopinavir/Ritonavir, n (%) 3 (6.5) 7 (17.5) 14 (20) 52 (28) 9 (23) 5 (50) 90 (23)
Azithromycin, n (%) 2 (4) 7 (17.5) 13 (20) 38 (20.5) 4 (10) 4 (40) 68 (17)
Other antibiotics*******, n (%) 4 (9) 4 (10) 7 (10) 22 (12) 12 (31) 4 (40) 53 (14)
Systemic corticosteroids, n (%) 1 (2) 3 (7.5) 5 (7) 19 (10) 5 (13) 4 (40) 37 (9.5)
NSAIDs, n (%) 4 (9) 1 (2.5) 3 (4) 10 (5) 17 (43.5) 0 (0) 35 (9)
Tocilizumab (IL-6 inhibitors), n (%) 2 (4) 2 (5) 4 (6) 9 (5) 5 (13) 0 (0) 22 (6)
Bevacizumab, n (%) 0 (0) 2 (5) 4 (6) 6 (3) 0 (0) 0 (0) 12 (3)
LMWH, n (%) 0 (0) 0 (0) 0 (0) 1 (0.5) 9 (23) 1 (10) 11 (3)
Remdesivir, n (%) 1 (2) 1 (2.5) 2 (3) 4 (2) 2 (5) 1 (10) 11 (3)
Serpin inhibitors, n (%) 1 (2) 1 (2.5) 1 (1) 3 (2) 0 (0) 0 (0) 6 (1.5)
Omeprazole, n (%) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (10) 2 (0.5)
JAK inhibitors, n (%) 2 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (0.5)
Telmizartan, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.5) 0 (0) 1 (0.2)
Fondaparinux, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.5) 0 (0) 1 (0.2)
Darunavir/cobicistat, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (0.2)
IVIG, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (0.2)
(Continued)
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COVID-19 severity********, N 96 63 79 201 44 4 487
Mild, n (%) 79 (82) 32 (51) 40 (51) 79 (39) 2 (5) 2 (50) 234 (48)
Moderate, n (%) 13 (14) 18 (29) 28 (35) 86 (43) 12 (27) 0 (0) 157 (32)
Severe, n (%) 4 (4) 13 (21) 11 (14) 36 (18) 30 (68) 2 (50) 96 (20)
Death, n (%)********* 4 (3.6) 3 (3.4) 2 (2.2) 7 (3.1) 10 (18.2) 1 (3.2) 27 (4.5)
FDP, fibrinogen degradation product; PT, prothrombin time; LFT, liver function test.
*Number of patients that their gender is reported in the articles.
**Number of patients that articles mentioned their specific treatment for the lesions.
***Number of patients reported having comorbidities in the articles.
****E.g., atopic dermatitis, chronic urticaria, melanoma, alopecia areata, hidradenitis suppurativa.
*****Number of patients that articles mentioned their associated symptoms.
******Number of patients that their laboratory findings are reported in the articles.
*******Including mainly Levofloxacin, Amoxicillin–clavulanic acid, Cefpodoxime, Ceftriaxone, Piperacillin/tazobactam, Cefoperazone-sulbactam.
********Mild: outpatients, Moderate: hospitalized patients (with or without supplemental oxygen), Severe: ICU added patients, non-invasive/invasive ventilation or ECMO required, patients
with acute respiratory distress syndrome (ARDS).
*********N is the total number of cases in each category; Chilblain-like lesions (110), Vesicular lesions (89), Urticaria-like lesions (89), Maculopapular lesions (223), Vascular lesions (55),
Miscellaneous (31), Total (597).
The overall frequency of cutaneousmanifestations in COVID-
19 patients was 5.95%, with a range from 0.2% up to 20.4% in
different studies (6, 65).
Although skin presentations of COVID-19 are well described,
the pathogenesis of skin lesions remains unknown. The direct
viral invasion of the skin cells may be one possibility.
Angiotensin-converting enzyme 2 (ACE2) is known as a ligand
for the Spike protein of SARS-CoV-2 for entering human cells
(66). There is a high expression of ACE2 on keratinocytes and
sweat gland cells, respectively (67, 68). Thus, SARS-CoV-2 can
directly infect keratinocytes resulting in necrosis. This hypothesis
is consistent with our histologic findings which demonstrated
the epidermal and adnexal necrosis in all skin lesions except
vesicular rashes. According to Amatore et al., neither viral-
induced cytopathic alterations nor intranuclear inclusions were
seen in skin biopsies (35). However, SARS-CoV-2 spike and
envelope proteins were detected in the endothelial cells of
damaged skin in two cases with purpuric rashes (22). RT-PCR for
SARS-CoV-2 was performed on skin samples of some patients
and was negative in all of them. Since the nasopharyngeal swabs
of these patients were positive simultaneously, we assume that it
can be a false negative result due to a small viral load or technical
problems. Further research is urgently needed.
Skin lesions during SARS-CoV2 infection might be immune-
related phenomena. It has been shown that the presence of
virus RNA in blood is related to greater severity of infection
(69). Viremia is also associated with the levels of cytokines
and growth factors in a dose-dependent manner with markedly
higher levels in patients suffering from more severe COVID-19
(69). Recognition of the viral RNA by Toll-free receptors like
TLR7 stimulates the intracellular signaling pathways which in
turn enhance the cytokine secretion (69).
In a group of patients, with the end of the first week of the
infection, a sharp increase in inflammatory cytokines such as
interleukin (IL)1, IL2, IL7, IL10, granulocyte colony-stimulating
factor (G-CSF), tumor necrosis factor (TNF) α and interferon
(IFN)-g occurs. Overactivation of immune responses followed by
pro-inflammatory cytokines increase may result in a “cytokine
storm” which is an immune pathological condition (69–71).
Increased cytokines allow them to access the skin, where they
stimulate various cells, including lymphocytes, dendritic cells,
macrophages, neutrophils, monocytes, and Langerhans cells to
cause various skin manifestations (22, 69). Maybe a hyperviremia
state is responsible for vascular lesions in severe COVID-19
patients. We suggest further investigations on the viral load
levels among patients with vascular lesions compared with other
skin manifestations.
The antigen-antibody complex can lead to complement
activation and subsequent mast cell degranulation. This
mechanism is suggested particularly for the urticaria-like
lesions (43).
A low or delayed interferon response may result in
uncontrolled viral replication followed by a subsequent cytokine
storm which can lead to severe disease (72). Activation of the
host immune system in response to viral antigen deposition may
result in vascular damage in COVID-19 infection (73). It seems
that high levels of type 1 interferon response, a critical factor in
immunity against viral agents, is associated with chilblain-like
lesions and mild disease (15, 72, 74). Activation and aggregation
of cytotoxic CD8+ T cells and B cells also lead to lymphocytic
thrombophilic arteritis and destruction of keratinocytes (21, 22).
Nests of Langerhans cells are seen in most of the COVID-19
skin lesion biopsies and have been also reported in another
viral-induced skin dermatitis-like pytriasis rosea (75).
Coinfection with other viruses is another potential possibility
for COVID-19 related cutaneous manifestations. Some skin
lesions in COVID-19 patients are very similar to rashes induced
by other viruses like parvovirus18, herpes simplex virus type
1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and
poxviruses, both clinically and histologically. It is probable that
because of the attenuation of the immune system, COVID-19
patients are susceptible to coinfection with or relapse of the
other viral exanthems. This hypothesis is strongly suggested
for vesicular and some miscellaneous lesions (e.g., erythema
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multiform) due to their unique histologic findings compared
to other skin lesions of COVID-19 (24, 32, 37). A study
reported four COVID-19 patients presenting diffuse vesicular
lesions which microbiological and serological investigations
demonstrated varicella infection (24). Thus, in COVID-19
patients with vesicular lesions, physicians need to investigate
other possible etiological factors other than SARS-CoV-2.
Coagulopathy and vasculitis are other possible reasons for
skin lesions during COVID-19. Evidence shows that COVID-
19 patients are predisposed to coagulopathy and subsequent
thrombotic events (76). It seems to be a result of inflammatory
cytokine release, hypoxia, and other illness or therapeutic risk
factors (76). Microvascular thrombosis of dermal vessels leads to
ischemia or vasculitis mainly seen in chilblain-like or vascular
lesions. Magro et al. focused on the role of the complement
factors activation, especially alternative and lectin pathways, and
subsequent thrombotic microvascular injuries (22). Evidence
for this hypothesis is the elevated levels of CH50, C3, and C4
in blood samples as well as significant vascular depositions of
C5b-9, C3d, and C4d in the dermis of skin specimens (22).
According to our histologic findings mentioned in RESULT,
vascular thrombosis was reported in almost all skin biopsies
(except vesicular lesions). This finding across with the increased
level of D-dimer, fibrinogen, and prolonged PT and INR in most
patients is in favor of this hypothesis. Another presentation of
coagulopathy in COVID-19 patients is hemorrhagic events and
subsequent dermatologic manifestations (petechiae, purpura,
and livedo). These manifestations are not specific to SARS-CoV-
2. Schneider et al. reported a petechial rash associated with
coronavirus NL63 (77, 78).
Extremely dilated blood vessels were introduced as a
diagnostic histological finding for SARS-CoV-2 by Zengarini
et al. (28). There are other reports of vasodilation and
telangiectatic vessels in the dermis. With this finding, Magro
et al. explained a possible pathway in which dysfunction of ACE2
(due to SARS-CoV-2 binding) and subsequent elevated level of
angiotensin2 can result in high activation of endothelial nitric
oxide synthase (eNOS) and ensuing vasodilation (22).
Drug-induced eruptions may occur during COVID-19.
COVID-19 patients usually use a set of medications that
potentially can cause cutaneous rashes. The current study
found that paracetamol, azithromycin, hydroxychloroquine,
lopinavir/ritonavir, and remdesivir were the most common
medications used for COVID-19 patients. Paracetamol has been
reported to cause asymmetrical drug-related intertriginous and
flexural exanthema (STRIFE) (16). However, in Mahé et al. study,
despite keeping the drug, skin lesions disappeared; that is very
uncommon in drug reactions (16). Najarian et al. mentioned
that maculopapular lesions of their patient could be according
to azithromycin use or hypersensitivity reaction to azithromycin
due to concurrent viral infection (20).
Hydroxychloroquine that has been used in 45% of all
the cases (mentioned in Result) is one of the most likely
medications to cause different skin rashes. Acute generalized
exanthematous pustulosis (AGEP), erythroderma, urticaria, and
erythema multiform are some of the skin lesions that have
been reported in connection with hydroxychloroquine (79–81).
However, Robustelli et al. mentioned that the skin lesion
developed 3 weeks after discontinuation of the drug (42). As
a conclusion, most of our reviewed articles considered the
potential possibility of drug-induced exanthems but in almost
all cases, dermatologic manifestations preceded the drug intake
or the rashes disappeared despite the continuation of drugs
(5, 7, 16, 20, 23, 37, 42, 43). So it is very unlikely that
current COVID-19 medications are responsible for the reported
skin lesions.
In our study, the prevalence of comorbidities in COVID-
19 patients with skin manifestations is about 17.9% mainly
reported in patients with maculopapular lesions. History of
serious comorbidities like cardiovascular disease, hypertension,
and obstructive lung disease was mostly reported in patients
with vascular lesions; suggesting that patients with these skin
manifestations are more complicated cases and need more
attention. Interestingly, immune disorders were more common
in patients with chilblain-like lesions. This finding is not
reported yet and we suggest it to be focused on due to the
possible relationship with the etiology and pathophysiology of
these lesions.
Fever, cough, and dyspnea were more frequent in patients
with vascular lesions and less frequent in patients with chilblain-
like lesions. Also, 17% of patients with chilblain-like lesions were
asymptomatic regarding systemic symptoms. Astonishingly,
headache, dysosmia/dysgeusia, nasal congestion/coryza,
and irritability/confusion were more common in patients
with vesicular lesions. This finding can demonstrate the
probable link between vesicular lesions and neurological
manifestations. Future investigations are required to clarify
the issue.
LIMITATIONS
There were limited articles that mentioned complete data about
all the items including the disease severity and outcome of the
COVID-19 patients with dermatologic presentations. Another
limitation was the absence of data about the COVID-19 patients
without skin manifestations. Future cohort studies are required
to compare the severity and prognosis of the disease in patients
with and without skin manifestations, considering other related
characteristics. Such studies help to better understand the
prognostic value of the cutaneous manifestations in COVID-
19 patients.
CONCLUSIONS
Cutaneous lesions occur most often in middle age individuals
at the same time or after the systemic symptoms of COVID-19.
Urticaria-like lesions commonly (47%) occurred at the same time
with other symptoms. It may suggest that urticaria-like lesions
may be a diagnostic sign for COVID-19. A maculopapular rash
is the main reported skin involvement in COVID-19 patients
and is associated with intermediate severity of the disease. The
mere occurrence of skin manifestations in COVID-19 patients
is not an indicator for the disease severity, and it highly
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depends on the type of skin lesions. Chilblain-like and vascular
lesions are the ends of a spectrum in which from chilblain-like
to vascular lesions, the severity of the disease increases, and
the patient’s prognosis worsens. We highly suggest emergency
and general practitioners to evaluate the suspected COVID-19
patients for any cutaneous manifestations. Those with vascular
lesions should also be considered as high-priority patients for
further medical care.
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